Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial

被引:12
|
作者
Huang, Yu [1 ]
Chen, Jinnan [1 ]
Ding, Zhaohui [1 ]
Chen, Xi [1 ]
Liang, Xiao [1 ]
Zeng, Xin [2 ]
Xu, Fei [2 ]
Han, Yuehua [3 ]
Lu, Hong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab Di, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China
[3] Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Helicobacter pylori; Minocycline; Tetracycline; Rescue therapy; ANTIBIOTIC-RESISTANCE; 2ND-LINE REGIMENS; AMOXICILLIN; METRONIDAZOLE; ERADICATION; DOXYCYCLINE; INFECTION; EFFICACY; SAFETY; SUSCEPTIBILITY;
D O I
10.1007/s00535-023-01991-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundTo compare the efficacy and tolerability of minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) rescue treatment.MethodsThis study was a multi-center, randomized-controlled, non-inferiority trial. Refractory H. pylori-infected subjects with multiple treatment-failure were randomly (1:1) allocated to receive 14-day therapy with esomeprazole 20 mg b.i.d, bismuth 220 mg b.i.d, plus metronidazole 400 mg q.i.d and minocycline 100 mg b.i.d (minocycline group) or tetracycline 500 mg q.i.d (tetracycline group). Primary outcome was H. pylori eradication rate evaluated by C-13-urea breath test at least 6 weeks after the end of treatment. Antibiotic resistance was determined using E test method.ResultsThree hundred and sixty-eight subjects were randomized. The eradication rates in minocycline group and tetracycline group were 88.0% (162/184, 95% CI 83.3-92.8%) and 88.6% (163/184, 95% CI 83.9-93.2%) in intention-to-treat analysis, 98.0% (149/152, 95% CI 95.8-100%) and 97.4% (150/154, 95% CI 94.9-99.9%) in per-protocol analysis, 93.1% (162/174, 95% CI 89.3-96.9%) and 93.1% (163/175, 95% CI 89.4-96.9%) in modified intention-to-treat analysis. Minocycline, tetracycline and metronidazole resistance rates were 0.7%, 1.4% and 89.6%, respectively. Non-inferiority of minocycline was confirmed (P < 0.025). Metronidazole resistance did not affect the efficacy of either therapy. The two therapies exhibited comparable frequencies of adverse events (55.4% vs. 53.3%); almost half of them were mild. Dizziness was the most common adverse events in the minocycline group.ConclusionsMinocycline can be an alternative for tetracycline in bismuth-containing quadruple therapy for H. pylori empirical rescue treatment, irrespective of metronidazole resistance. However, relatively high incidence of adverse events in both regimens should be emphasized.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 50 条
  • [21] Meta-Analysis of Levofloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy as Second-Line Treatment in the Eradication of Helicobacter pylori
    Marin, Alicia C.
    McNicholl, Adrian G.
    Gisbert, Javier P.
    GASTROENTEROLOGY, 2012, 142 (05) : S483 - S483
  • [22] Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
    Kim, Ji Yoon
    Kim, Sang Gyun
    Cho, Soo-Jeong
    MEDICINE, 2023, 102 (48) : E36310
  • [23] Second line bismuth-containing quadruple therapy for Helicobacter pylori eradication in Korea
    Cho, M.
    Hwang, H.
    Kim, Y.
    Lim, C.
    Oh, J.
    HELICOBACTER, 2019, 24
  • [24] Evaluating vonoprazan bismuth-containing triple therapy versus quadruple therapy for Helicobacter pylori
    Tang, W-Z
    Li, J-Z
    Liu, T-H
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024,
  • [25] Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study
    Huang, Yu
    Qiu, Shuhan
    Guo, Yixian
    Chen, Jinnan
    Li, Meixuan
    Ding, Zhaohui
    Zhang, Wei
    Liang, Xiao
    Lu, Hong
    HELICOBACTER, 2024, 29 (05)
  • [26] A meta-analysis of randomized controlled trials of bismuth-containing quadruple therapy combined with probiotic supplement for eradication of Helicobacter pylori
    司小北
    China Medical Abstracts(Internal Medicine), 2017, 34 (04) : 208 - 209
  • [27] Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
    Lim, Hyun
    Bang, Chang Seok
    Shin, Woon Geon
    Choi, Jae Ho
    Soh, Jae Seung
    Kang, Ho Suk
    Yang, Young Joo
    Hong, Ji Taek
    Shin, Suk Pyo
    Suk, Ki Tae
    Lee, Jae Jun
    Baik, Gwang Ho
    Kim, Dong Joon
    MEDICINE, 2018, 97 (46)
  • [28] Susceptibility-based tailored vs. empiric amoxicillin modified bismuth quadruple therapy as Helicobacter pylori therapy: a multicenter randomized controlled trial
    Lu, H.
    HELICOBACTER, 2018, 23
  • [29] High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of helicobacter pylori infection: A meta-analysis of randomized controlled trials
    Zhang, Chong
    Zhang, Jun
    Cheng, Yu-Jie
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2023, 29 (02): : 88 - 94
  • [30] Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative,open trial
    Youn I Choi
    Jun Won Chung
    Dong Kyun Park
    Kyoung Oh Kim
    Kwang An Kwon
    Yoon Jae Kim
    Ja Young Seo
    World Journal of Gastroenterology, 2019, (46) : 6743 - 6751